Form 4: Solen Therapeutics CEO Anish Bhatnagar Sells Shares to Cover Tax Obligations

Anish Bhatnagar, CEO of Soleno Therapeutics, sold shares of common stock on July 1, 2024, to cover tax withholding obligations related to the vesting of restricted stock units.

Summary

• On July 1, 2024, Anish Bhatnagar, the CEO of Soleno Therapeutics, sold shares of the company's common stock.
• The sales were executed in two transactions to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs).
• In the first transaction, 4,198 shares were sold at a weighted average price of $41.2217, with individual prices ranging from $40.39 to $41.38.
• In the second transaction, 15,058 shares were sold at a weighted average price of $41.6254, with individual prices ranging from $41.39 to $42.08.
• Following these transactions, Bhatnagar directly owns 133,534 shares of Soleno Therapeutics common stock, some of which are RSUs representing a contingent right to receive one share of common stock subject to vesting schedules and conditions.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports stock sales for tax purposes, a routine financial activity.

Industry Context

Executive stock sales are a common occurrence, often related to compensation and tax planning. The market typically analyzes these sales in the context of the executive's overall holdings and the company's performance.

Stakeholder Impact

• The stock sale may have a minor impact on shareholders due to the increased supply of shares in the market, but it is unlikely to be significant given the relatively small number of shares sold.

Key Dates